News
ORKA
92.51
+1.67%
1.52
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
Benzinga · 2d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (GUTS) and Oruka Therapeutics (ORKA)
TipRanks · 3d ago
Weekly Report: what happened at ORKA last week (0824-0828)?
Weekly Report · 5d ago
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)
Seeking Alpha · 08/27 23:09
Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines
TipRanks · 08/26 12:15
XBI, TWST, ORKA, APGE: Large Inflows Detected at ETF
NASDAQ · 08/25 14:54
Oruka Appoints Todd Edwards As CCO Ahead Of ORKA-001 & ORK-002 Commercialization
NASDAQ · 08/25 02:01
Press Release: Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Dow Jones · 08/24 20:01
Weekly Report: what happened at ORKA last week (0817-0821)?
Weekly Report · 08/24 09:01
Oruka Therapeutics files $1B mixed securities shelf
TipRanks · 08/21 20:25
Show Me The Money: ORKA Makes A Splash With A 500%+ Gain; More Catalysts Ahead
NASDAQ · 08/21 11:20
Biotech Stocks At 52-Week Highs - ETON +44%, DXCM, ORKA, CON, ATAI
NASDAQ · 08/17 11:37
Weekly Report: what happened at ORKA last week (0810-0814)?
Weekly Report · 08/17 09:01
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 08/15 14:30
Oruka Therapeutics (ORKA) Has a New Rating from Wedbush
TipRanks · 08/12 05:16
Analysts Are Bullish on These Healthcare Stocks: Oruka Therapeutics (ORKA), Zura Bio (ZURA)
TipRanks · 08/11 20:40
Jefferies Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 08/11 14:56
Oruka Therapeutics Price Target Maintained With a $200.00/Share by Guggenheim
Dow Jones · 08/11 14:38
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Benzinga · 08/11 14:28
More
Webull provides a variety of real-time ORKA stock news. You can receive the latest news about Oruka Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).